Shahin MS - Search Results

1

Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.

Buller RE, Shahin MS, Horowitz JA, Runnebaum IB, Mahavni V, Petrauskas S, Kreienberg R, Karlan B, Slamon D, Pegram M. Buller RE, et al. Among authors: shahin ms. Cancer Gene Ther. 2002 Jul;9(7):567-72. doi: 10.1038/sj.cgt.7700473. Cancer Gene Ther. 2002. PMID: 12082456

2

The glutathione S-transferase M1 genotype in ovarian cancer.

Lallas TA, McClain SK, Shahin MS, Buller RE. Lallas TA, et al. Among authors: shahin ms. Cancer Epidemiol Biomarkers Prev. 2000 Jun;9(6):587-90. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 10868693

3

The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.

Shahin MS, Hughes JH, Sood AK, Buller RE. Shahin MS, et al. Cancer. 2000 Nov 1;89(9):2006-17. doi: 10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.3.co;2-z. Cancer. 2000. PMID: 11064359

4

p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang.

Buller RE, Shahin MS, Holmes RW, Hatterman M, Kirby PA, Sood AK. Buller RE, et al. Among authors: shahin ms. Am J Obstet Gynecol. 2001 Apr;184(5):891-902; discussion 902-3. doi: 10.1067/mob.2001.113856. Am J Obstet Gynecol. 2001. PMID: 11303196

5

The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.

Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman-Zogg M, Anderson B, Sorosky JI, Kirby PA. Buller RE, et al. Among authors: shahin ms. Clin Cancer Res. 2001 Apr;7(4):831-8. Clin Cancer Res. 2001. PMID: 11309330

6

Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy.

Sood AK, Shahin MS, Sorosky JI. Sood AK, et al. Among authors: shahin ms. Gynecol Oncol. 2001 Dec;83(3):599-600. doi: 10.1006/gyno.2001.6439. Gynecol Oncol. 2001. PMID: 11733979

7

Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.

Hanjani P, Nolte S, Shahin MS. Hanjani P, et al. Among authors: shahin ms. Gynecol Oncol. 2002 May;85(2):278-84. doi: 10.1006/gyno.2002.6593. Gynecol Oncol. 2002. PMID: 11972388 Clinical Trial.

8

Failure of BRCA1 dysfunction to alter ovarian cancer survival.

Buller RE, Shahin MS, Geisler JP, Zogg M, De Young BR, Davis CS. Buller RE, et al. Among authors: shahin ms. Clin Cancer Res. 2002 May;8(5):1196-202. Clin Cancer Res. 2002. PMID: 12006538

9

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.

Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M. Buller RE, et al. Cancer Gene Ther. 2002 Jul;9(7):553-66. doi: 10.1038/sj.cgt.7700472. Cancer Gene Ther. 2002. PMID: 12082455 Clinical Trial.

10

Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.

Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sood AK, et al. Among authors: shahin ms. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6080-5. doi: 10.1158/1078-0432.CCR-04-0574. Clin Cancer Res. 2004. PMID: 15447993 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters